Psilocibin: Current Evidence, Safety Signals, and Challenges in Assessing Potential Multi-Organ Effects
Biomedicines July 6, 2026 Kasper Buczma, Katarzyna Kamińska, Kaja Kasarełło et al.
Background/Objectives: Psilocibin (PSY), a serotonergic hallucinogen, has attracted increasing scientific interest due to its therapeutic potential, particularly in treatment-resistant depression. In parallel with its growing clinical and research relevance, important questions have emerged regarding its safety profile, including potential effects on the liver, kidneys, cardiovascular system,...